Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Data to Boehringer Ingelheim
Owkin official newsroom · 行业原文收录 · 来源发布：Wed Sep 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:56 GMT+0000 (Coordinated Universal Time)
已保存的原文节选
NEW YORK & PARIS — Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertak
以上为带出处的原文节选，完整内容请阅读原始链接。自动收录与主题分类不等于事实核验。